4-乙酰氧基萘-2-羧酸乙酯 | 33295-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-乙酰氧基萘-2-羧酸乙酯
• 英文名称: ethyl 4-acetoxynaphthalene-2-carboxylate
• 英文别名: ethyl 4-acetoxy-2-naphthoate；ethyl 4-acetyloxynaphthalene-2-carboxylate
• CAS: 33295-46-4
• 化学式: C₁₅H₁₄O₄
• 分子量: 258.274
• InChiKey: KPGGFWPXWVPQBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-乙酰氧基萘-2-羧酸乙酯 在 palladium on activated charcoal palladium diacetate 、 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 lithium aluminium tetrahydride 、 dimethyl sulfide borane 、 1,3-双(二苯基膦)丙烷 、 氢气 、 双氧水 、 sodium hydride 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 tetrahydrofuran-hydrogen chloride 、 silver carbonate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 反应 11.74h， 生成 3-chloro-1,2,3,4-tetrahydrophenanthren-9-ol
  参考文献：
  名称：

  Synthesis and Evaluation of a Carbocyclic Analogue of the CC-1065 and Duocarmycin Alkylation Subunits:  Role of the Vinylogous Amide and Implications on DNA Alkylation Catalysis

  摘要：

  The synthesis and chemical properties of 1,2,9,9a-tetrahydro-1H-cyclopropa[c]benz[e]inden-4-one (CBIn, 10), a carbocyclic C-ring analogue of the alkylation subunits of CC-1065 and the duocarmycins, are detailed. The core structure of CBIn was prepared with an intramolecular Heck reaction for assembly of the key tricyclic skeleton and a final Winstein Ar-3' spirocyclization to install the reactive cyclopropane. A study of the CBIn solvolysis reactivity, regioselectivity, and mechanism revealed that removal of the nitrogen and resulting vinylogous amide stabilization increased the reactivity 3200x (pH 3) and reversed the inherent regioselectivity, but did not alter the S(N)2 reaction mechanism. Thus, the vinylogous amide found in the naturally occurring alkylation subunits is responsible for their unusual stability and significantly impacts the regioselectivity without altering the inherent S(N)2 mechanism of nucleophilic addition. More importantly, this solvolysis reactivity proved independent of pH throughout the range of 4-12 including the physiologically relevant range of 5.0-8.0 where CBI is completely stable. Rate constants of 0.093 +/- 0.001 M(-1) s(-1) and 4.2 +/- 0.4 x 10(-5) s(-1) for the respective acid-catalyzed and uncatalyzed reactions were established, and the uncatalyzed reaction dominates at pH greater than or equal to 4. These observations have important implications on the source of catalysis for the CC-1065/duocarmycin DNA alkylation reaction supporting the recent proposal that it is not derived from acid catalysis and C4 carbonyl protonation but rather a DNA binding-induced conformational change that disrupts the cross-conjugated vinylogous amide stabilization.

  DOI：

  10.1021/jo981698q
• 作为产物：
  描述：

  (E)-4-phenyl-3-carbethoxyethylbut-3-enoic acid 、 乙酸酐 在 sodium acetate 作用下， 反应 3.0h， 生成 4-乙酰氧基萘-2-羧酸乙酯
  参考文献：
  名称：

  Gabbutt, Christopher D.; Hepworth, John D.; Heron, B. Mark, Heterocycles, 2004, vol. 63, # 3, p. 567 - 582

  摘要：

  DOI：

文献信息

• [EN] MCL-1 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MCL-1 ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ASTRAZENECA AB

  公开号：WO2018178226A1

  公开（公告）日：2018-10-04

  Disclosed are Mcl-1 inhibitors, pharmaceutical compositions comprising the same and methods of using the same.

  揭示了Mcl-1抑制剂，包括相同物质的药物组合物以及使用相同物质的方法。
• A Total Synthesis of Yellowish Aphid Pigment Furanaphin through Fries Rearrangement Assisted by Boron Trifluoride-Acetic Acid Complex
  作者：Tetsuto Tsunoda、Taichi Nishimura、Takeki Iwata、Hironori Maegawa、Takeshi Nishii、Masami Matsugasako、Hiroto Kaku、Mitsuyo Horikawa、Makoto Inai

  DOI：10.1055/s-0031-1290429

  日期：2012.7

  The yellowish aphid pigment furanaphin, isolated from Aphis spiraecola and possessing cytotoxicity against HL-60 (human promyelocytic leukemia-60) cells, was synthesized by utilizing the Fries rearrangement assisted with a BF3·2AcOH complex as a key step. It was confirmed that the complex effectively mediated the reaction even though the compounds had an electron-withdrawing substituent.

  以BF3·2AcOH复合物辅助的Fries重排为关键步骤，从Aphis spiraecola中分离出对HL-60（human promyelocyticemia-60）细胞具有细胞毒性的黄色蚜虫色素呋喃酚。证实即使化合物具有吸电子取代基，该配合物也有效地介导了反应。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Quinoline-carboxamide derivatives as P2Y12 antagonists
  申请人：Nazare Marc

  公开号：US08669266B2

  公开（公告）日：2014-03-11

  The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述权利要求中指定的含义。公式I的化合物是有价值的药理活性化合物。它们在血小板上表现出强烈的抗聚集作用，因此具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常可以应用于存在不希望的血小板ADP受体P2Y12激活或需要抑制血小板ADP受体P2Y12的治疗或预防的情况。此外，本发明还涉及公式I的化合物的制备方法，它们的使用，特别是作为药物的活性成分，以及包含它们的药物制剂。
• SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
  申请人：LUPIN ATLANTIS HOLDINGS SA

  公开号：US20160214924A1

  公开（公告）日：2016-07-28

  The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

  本发明涉及公式（I）的萘化合物及其药学上可接受的盐，其中取代基如本文所述，并且它们在医学上用于治疗与钙感受受体调节剂（Ca SR）调节剂相关的疾病和紊乱。本发明还涉及含有这种化合物的药物组合物，用于治疗与钙感受受体调节剂（Ca SR）通道调节剂相关的疾病和紊乱。